Id: acc0175
Group: 2sens
Protein: STAT5
Gene Symbol: STAT5A
Protein Id: P42229
Protein Name: STA5A_HUMAN
PTM: phosphorylation
Site: Tyr694
Site Sequence: PVLAKAVDGYVKPQIKQVVPE
Disease Category: Cancer
Disease: Leukemia
Disease Subtype: AML-M5
Disease Cellline: MV4-11
Disease Info:
Drug: cabozantinib
Drug Info: "Cabozantinib is a multi-targeted tyrosine kinase inhibitor that acts on MET, VEGFR1/2/3, RET, AXL, and other kinases, approved for the treatment of progressive metastatic medullary thyroid cancer, advanced renal cell carcinoma after prior anti-angiogenic therapy, and hepatocellular carcinoma following sorafenib failure. "
Effect: modulate
Effect Info: "Cabozantinib inhibits the phosphorylation of FLT3, STAT5, AKT, and ERK, thereby inhibiting and preventing the growth of MV4 - 11 tumor cells."
Note:
Score: 4.0
Pubmed(PMID): 27060207
Sentence Index:
Sentence:

Sequence & Structure:

MAGWIQAQQLQGDALRQMQVLYGQHFPIEVRHYLAQWIESQPWDAIDLDNPQDRAQATQLLEGLVQELQKKAEHQVGEDGFLLKIKLGHYATQLQKTYDRCPLELVRCIRHILYNEQRLVREANNCSSPAGILVDAMSQKHLQINQTFEELRLVTQDTENELKKLQQTQEYFIIQYQESLRIQAQFAQLAQLSPQERLSRETALQQKQVSLEAWLQREAQTLQQYRVELAEKHQKTLQLLRKQQTIILDDELIQWKRRQQLAGNGGPPEGSLDVLQSWCEKLAEIIWQNRQQIRRAEHLCQQLPIPGPVEEMLAEVNATITDIISALVTSTFIIEKQPPQVLKTQTKFAATVRLLVGGKLNVHMNPPQVKATIISEQQAKSLLKNENTRNECSGEILNNCCVMEYHQATGTLSAHFRNMSLKRIKRADRRGAESVTEEKFTVLFESQFSVGSNELVFQVKTLSLPVVVIVHGSQDHNATATVLWDNAFAEPGRVPFAVPDKVLWPQLCEALNMKFKAEVQSNRGLTKENLVFLAQKLFNNSSSHLEDYSGLSVSWSQFNRENLPGWNYTFWQWFDGVMEVLKKHHKPHWNDGAILGFVNKQQAHDLLINKPDGTFLLRFSDSEIGGITIAWKFDSPERNLWNLKPFTTRDFSIRSLADRLGDLSYLIYVFPDRPKDEVFSKYYTPVLAKAVDGYVKPQIKQVVPEFVNASADAGGSSATYMDQAPSPAVCPQAPYNMYPQNPDHVLDQDGEFDLDETMDVARHVEELLRRPMDSLDSRLSPPAGLFTSARGSLS

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
STAT5A-Tyr694
Cancer Intensity
BRCA -0.21
COAD 0.081
HGSC 2.396
ccRCC 0.242
GBM -0.214
HNSC 0.119
LUAD 0.595
LUSC 0.038
non_ccRCC -1.223
PDAC -0.376
UCEC -1.449

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
Y 694 D Head and neck squamous cell carcinoma Phosphorylation 21281788
Y 694 D Sjogren's syndrome Phosphorylation 36072585
Y 694 N Large granular lymphocytic leukemia Phosphorylation 23596048
Y 694 U Glioblastoma Phosphorylation 22729867
Y 694 U Colon cancer Phosphorylation 23733954
Y 694 U Human immunodeficiency virus infectious disease Phosphorylation 21716071

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: